Suramin is a century-old injectable medication primarily used to treat African sleeping sickness, a parasitic infection spread by tsetse flies. It was one of the first drugs ever developed through a systematic medicinal chemistry program, and it remains on the World Health Organization’s List of Essential Medicines today. While its original purpose is narrow, suramin has drawn renewed scientific interest for its effects on cell signaling, with early-stage research exploring potential roles in conditions ranging from autism spectrum disorder to viral infections.
Origins and Development
Suramin’s story begins in the early 1900s with Paul Ehrlich’s discovery that a blue dye called trypan blue could kill trypanosomes, the parasites responsible for sleeping sickness. Chemists at the German pharmaceutical company Bayer set out to create colorless, more potent versions of the compound. In 1916, Oskar Dressel, Richard Kothe, and Bernhard Heymann synthesized what they simply called “molecule 205.” That molecule was suramin, and by 1922 it was being used to treat patients with African sleeping sickness. It was a landmark in drug design: rather than stumbling on a natural remedy, researchers had methodically built a drug from scratch.
How Suramin Works
Suramin is a large, negatively charged molecule that interferes with multiple biological processes at once. Its original value comes from its ability to kill Trypanosoma parasites in the blood and lymph system, though the exact mechanism against these parasites is still not fully mapped out.
What scientists do know is that suramin blocks a family of signaling pathways driven by ATP, the molecule cells use as an energy currency and as a chemical messenger. Specifically, it inhibits P2X and P2Y receptors on cell surfaces. These receptors normally detect ATP released by neighboring cells and trigger responses like inflammation, immune activation, and nerve signaling. By blocking these receptors, suramin can dampen certain types of cellular communication. It also inhibits several enzymes, including reverse transcriptase (used by some viruses to copy their genetic material) and certain bacterial proteins involved in DNA repair.
This broad set of targets is both suramin’s strength and its limitation. It can affect many biological processes simultaneously, which makes it pharmacologically interesting but also contributes to its side effects.
Approved Medical Uses
Suramin’s primary approved use is treating the first stage of East African sleeping sickness, caused by the parasite Trypanosoma brucei rhodesiense. “First stage” means the infection is still in the blood and lymph and has not yet crossed into the brain. Suramin is the only drug effective for this specific stage of the East African form. It is given intravenously, typically starting with a small test dose of 4 to 5 mg/kg, followed by full doses of 20 mg/kg (up to 1 gram per injection) on days 1, 3, 7, 14, and 21.
Suramin was also the first drug used to treat river blindness (onchocerciasis), a parasitic disease caused by a worm spread through blackfly bites. It could kill both the adult worms and their offspring, but its toxicity was severe enough to require hospitalization. It has been almost entirely replaced by ivermectin, which is safer and can be distributed through mass drug programs without intensive medical supervision.
Side Effects and Safety Concerns
Suramin carries significant risks, which is a major reason its use is limited to life-threatening infections where no safer alternative exists. Kidney damage is the most common serious concern. Protein in the urine (albuminuria) occurs frequently, and more severe kidney dysfunction, including blood in the urine and elevated creatinine levels, can develop.
Immediate reactions during or shortly after infusion can include nausea, vomiting, fatigue, fever, hives, and in rare cases, shock, loss of consciousness, or death. Later reactions may involve skin rashes (sometimes severe and widespread), mouth sores, sensitivity to light, excessive tearing, and headache. Blood cell counts can drop, leading to anemia or increased susceptibility to infection. Nerve damage in the hands and feet, liver dysfunction, and adrenal insufficiency are also possible. Because of this profile, suramin is administered only in medical settings with close monitoring.
Antiviral Activity in the Lab
Suramin has shown the ability to block several viruses in laboratory experiments, including Zika, dengue, chikungunya, and SARS-CoV-2. The SARS-CoV-2 findings are particularly detailed: in cell cultures, suramin reduced viral levels by 100- to 1,000-fold depending on the dose. It achieved this at concentrations well below what would be toxic to the cells, with a selectivity index above 250, meaning there was a wide margin between the dose that stopped the virus and the dose that harmed cells.
Timing experiments revealed that suramin works by blocking an early step in viral infection, likely the moment the virus binds to or enters a cell. When treatment started even one hour after infection, it lost most of its effectiveness. This suggests suramin would need to be present before or at the moment of exposure to be useful, which limits its practical potential as an antiviral treatment. These results remain confined to laboratory studies and have not been tested in human clinical trials for any viral infection.
Early Research in Autism Spectrum Disorder
One of the more unexpected areas of suramin research involves autism spectrum disorder (ASD). The hypothesis, developed by Robert Naviaux at UC San Diego, centers on the idea that some features of autism may involve a “cell danger response,” where cells remain stuck in a defensive, inflammatory mode and use ATP signaling to maintain that state. Since suramin blocks ATP receptors, the theory proposes it might help normalize this cellular behavior.
A small initial trial found that children with ASD who received a single low-dose suramin infusion showed an average improvement of 1.6 points on the ADOS-2, a standard diagnostic measure for autism, while children receiving a placebo showed no change. A follow-up randomized trial tested two dose levels (10 mg/kg and 20 mg/kg) against a placebo. The lower dose group showed statistically significant improvement on a clinician-rated global impression scale compared to placebo. Interestingly, the higher dose did not show the same benefit, a pattern researchers are still working to explain.
These trials involved small numbers of participants, just 13 to 14 per group, and the improvements, while measurable, were modest. The results are enough to justify further study but far from enough to establish suramin as an autism treatment. The drug’s toxicity profile makes it unsuitable for routine or long-term use in its current form, and no regulatory body has approved it for this purpose.
Current Availability and Status
Suramin sodium is listed on the WHO’s 2023 Model List of Essential Medicines as a complementary drug for treating the initial phase of East African sleeping sickness. It is supplied as a powder for injection (1 gram per vial) and is primarily available through the WHO and specialized tropical disease programs rather than commercial pharmacies. In the United States, it is not FDA-approved but can be obtained from the CDC for treating confirmed cases of African trypanosomiasis. It is not available as an oral medication, and all administration requires intravenous infusion under medical supervision.